Testimonial
"I can't say enough good things about this product. Thank you for a quality of sleep and to my life that I have not known in years."
SCIENTIFIC ADVISORS
Dr. Philip Seeman
Dr. Seeman, an internationally recognized and respected scientist in the area of antipsychotic pharmacology, has been in the Department of Pharmacology at the University of Toronto since 1967. He served as its Chairman between 1977 and 1987 and currently is Professor Emeritus at the University of Toronto.
Dr. Seeman received his B.Sc. and M.D. at McGill University in Montreal. In 1966 he received a Ph.D. in Life Sciences at Rockefeller University where he worked with Dr. George Palade (1974 Nobel Laureate, Medicine/Physiology). Dr. Seeman's work from1964 to 1974 on the membrane actions of drugs led him to discover the antipsychotic receptor referred to as the dopamine D2 receptor. This research comprises an experimental backbone for the dopamine hypothesis of schizophrenia. In 1990~91 Dr. Seeman and his research group at the University of Toronto cloned three dopamine receptors: D1, D4 and D5.
As an educator, Dr. Seeman has trained over 100-graduate students and Fellows. He is a Fellow of the Royal Society of Canada. He has received 23-awards including the Lieber Award of the National Alliance for Research in Schizophrenia and Depression, the Stanley Dean Award of the American College of Psychiatrists, the Tanenbaum Award for Schizophrenia Research from the Canadian Psychiatric Research Foundation, the first Prix Galien award in North America, the Pasarow Foundation award in Neuropsychiatry, and the Killam Prize in Health Sciences from the Canada Council.
Dr. Charles Morin
Dr. Morin is Professor of Psychology and the Director of the Sleep Disorders
Centre at Laval University in Quebec City. He was on the faculty of the Medical
College of Virginia at Virginia Commonwealth University from 1986 to 1994.
Dr. Morin is a leading authority on insomnia treatment. He has been conducting
clinical research and treating patients with insomnia for over 20-years.
He has published extensively (including four books) and lectured internationally
on the topic and his research has been funded by the National Institute of
Mental Health and the Canadian Institutes of Health Research. A Diplomate
of the American Board of SleepDisorders Medicine, he received the Distinguished
Scientific Award for an Early Career Contribution to Psychology from the
American Psychological Association in 1995. He currently holds a Canada Research
Chair on Sleep Disorders and is President of the Canadian Sleep Society.
Dr. Oleh Hornykiewicz
Dr. Oleh Hornykiewicz is one of the world's leading neuroscientists.
He was the first to determine that Parkinson's disease results from too
little of one kind of neurotransmitter known as dopamine. His subsequent development
of L-dopa for the treatment of Parkinson's disease revolutionized the
treatment of that illness and remains the mainstay of therapy today. When he
did not receive the Nobel Prize for medicine in 2000, over 200-leading neurologists
world wide signed a letter protesting this decision to the Nobel selection
committee.
Dr. Hornykiewicz received his medical training at the University of Vienna in Austria. He has held full professorships concurrently at the University of Toronto in the Departments of Pharmacology and Psychiatry and in the Department of Biochemical Pharmacology at the University of Vienna. Dr. Hornykiewicz holds a number of prestigious international awards and has served as a scientific advisor on many boards and projects around the world.
Dr. Hornykiewicz is presently Professor Emeritus at both the University of Toronto and the University of Vienna. He continues to work out of the Brain Research Institute at the University of Vienna and is widely acknowledged as the leading authority on neurotransmitter function in diseased and normal brain. He brings a history of success as well as an ability to arrive at simple and elegant solutions to seemingly complex brain diseases.
